Vertex shares promising clinical data for its experimental non-opioid pain treatmentMarket Watch • 03/31/22
Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute PainBusiness Wire • 03/31/22
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR GeneBusiness Wire • 03/26/22
Are You Looking for a Top Momentum Pick? Why Vertex Pharmaceuticals (VRTX) is a Great ChoiceZacks Investment Research • 03/25/22
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney DiseaseBusiness Wire • 03/22/22
Nasdaq's Correction Could Be Nearly Over: 3 Stocks to Buy Sooner Rather Than LaterThe Motley Fool • 03/22/22
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should KnowZacks Investment Research • 03/16/22